78 results about "Renal glomerulus" patented technology

The invention relates to the technical field of treatment of chronic diseases of old people, and discloses a metabolic characteristic-based medicine dosage optimization method for chronic diseases of old people. The method comprises the following steps: acquiring drug metabolism parameters (including a plasma concentration peak value, a half-life period curve and the like) and organ function data (including a hepatocyte metabolism rate, a glomerular filtration rate and the like) of a plurality of monitoring nodes, arranging the drug metabolism parameters and the organ function data into a time sequence input vector, and extracting a dynamic feature vector by using a time convolution network and an adaptive filter network; performing feature crossing, pharmacokinetic constraint correction and feature enhancement processing, performing fusion to generate a joint feature vector, inputting the joint feature vector into a dose decision model to obtain an adjustment coefficient, and generating a drug dose interval with a safety threshold in combination with a historical drug use record. According to the method, multi-dimensional data integration and dynamic modeling are realized, the accuracy and safety of chronic disease medication of old people are improved, and the method is suitable for individualized treatment.

The invention discloses a glomerular segmentation method based on multi-scale Mama and dynamic sampling, and relates to the technical field of medical images. According to the method, the input multi-scale features are efficiently represented by using a continuous state transition mechanism, the structural association information extraction capability among different scales is enhanced, in addition, the problem of geometric distortion in dynamic sampling is solved by introducing position coding into the dynamic sampling method and adding position constraint information, and the dynamic sampling efficiency is improved based on a U-Net model. An MS-Mama module is gradually added in the encoder stage, and an existing bilinear interpolation method is replaced by a position sensing dynamic sampling module; and then, serialized representation is performed on multi-scale features based on a selective state space mechanism, the dependence of Mama on specific scale features is reduced, the ability of extracting heterogeneous morphological features of lesion glomerulus is enhanced, the boundary positioning precision of lesion glomerulus is enhanced by adding position constraint information, and the geometric distortion problem in dynamic sampling is solved.

The invention discloses a phosphatidylcholine gold nano CT (Computed Tomography) probe as well as a preparation method and application thereof, and belongs to the technical field of medical materials. The preparation method comprises the following steps: step S1, preparing a phosphatidylcholine ligand NH2-MPC; step S2, synthesis of a gold nanocluster GS-Au25 is carried out; and S3, the GS-Au25 is modified with a PC ligand, and the PC-Au25 is prepared. The ultra-small gold nano CT probe PC-Au25 with an Au25 gold nano cluster as a core and phosphatidylcholine PC as a surface ligand is obtained by optimizing and screening the core size and the surface ligand property of ultra-small gold nano particles. Wherein the 2-methacryloyloxyethyl phosphorylcholine is used as a PC ligand for the first time to modify the surfaces of the ultra-small gold nanoparticles, so that the surface modification of the ultra-small gold nanoparticles is realized, and the ultra-small gold nanoparticles can be efficiently and freely filtered through the kidney. The CT probe can be applied to the determination of the glomerular filtration rate through a CT imaging or blood test method.

The invention relates to the technical field of glomerular pathological section cell detection, and discloses a cell detection method and system for a glomerular pathological section image, and the method and system are used for dynamically adjusting a detection threshold value based on the morphological characteristics of cells in the glomerular pathological section image so as to solve the problem that the cell boundary is fuzzy. The contrast enhancement degree is regulated and controlled according to the non-uniform illumination characteristic of the image, so that the detail loss area in the low-quality image is optimized; adjusting classification model parameters according to different types of glomerular lesion features so as to reduce the probability of occurrence of false detection and missing detection; and setting the number of iterations of the segmentation algorithm according to the cell overlapping degree to realize complete separation of dense cells. Through the scheme of the embodiment of the invention, the problem of how to regulate and control the detection threshold value according to the morphological characteristics of the cells in the glomerular pathological section so as to solve the problem of fuzzy cell boundary can be solved, and the phenomena of false detection and missing detection are reduced by taking the lesion specific marker in the training data set as input guidance.

The invention belongs to the technical field of biological medicines, and particularly relates to application of poecilobdella manillensis in preparation of a medicine for treating renal injury. The invention provides a new application of poecilobdella manillensis in preparation of a medicine for treating renal injury, serum biochemical index detection proves that the poecilobdella manillensis can effectively reduce serum creatinine and blood urea nitrogen levels, increase serum albumin and total protein content, remarkably improve glomerular filtration function and protein metabolism function, and improve renal function. And the improvement degree of the traditional Chinese medicine composition is superior to that of a traditional Chinese medicine contrast. Although the curative effect is slightly poorer than that of a chemical drug group, the safety advantage is remarkable. The poecilobdella manillensis can comprehensively regulate renal function metabolism indexes, relieve kidney injury and avoid common side effects of chemical drugs, provides a new choice for clinical treatment of kidney injury, and is especially suitable for chronic kidney disease patients needing long-term treatment.

Described herein are methods for treating antibody mediated rejection (ABMR), especially chronic active ABMR (cABMR), of transplanted organs using clazakizumab. Human kidney transplant recipients with biopsy-proven cABMR, transplant glomerulopathy and who are donor-specific antibody positive showed stabilization of renal function and lowered DSA levels following clazakizumab treatment. The estimated glomerular filtration rate of the patients at six, 12 or even 18 months were stabilized, inflammatory markers of cABMR were reduced or stabilized, and inflammatory blood markers were reduced, since clazakizumab treatment.

The invention relates to a deep learning-based early-stage amyloidosis nephropathy identification and diagnosis method, belongs to the technical field of amyloidosis nephropathy identification, and solves the problem that early-stage amyloidosis cannot be accurately identified in the prior art. The method comprises the following steps: acquiring kidney pathological section images of different individuals to construct a training sample set; constructing a link model comprising a first region segmentation model, a second region segmentation model and a third region segmentation model; the first region segmentation model is used for segmenting a cortex region in the pathological image; the second region segmentation model is used for segmenting a glomerular region; the third region segmentation model is used for identifying amyloidosis of a glomerular region; training the link model based on the training sample set to obtain a trained link model; and inputting a to-be-identified kidney pathological section image into the trained link model to identify whether amyloidosis exists or not. And efficient and accurate early-stage amyloidosis identification is realized.

The invention provides a light microscope kidney pathological image analysis method based on artificial intelligence, and relates to the technical field of image recognition, and the method comprises the steps: obtaining a multi-mode light microscope kidney pathological image; performing positioning analysis on the glomerular structure of the multi-mode light microscope kidney pathological image by using the target detection network to obtain a position prediction result; classifying the position prediction result by using a classification network to obtain a classification result; utilizing a semantic segmentation network to perform pathological feature quantitative extraction on the complete glomerulus in the classification result to obtain a quantitative pathological index; and performing multi-level feature fusion on the classification result and the quantitative pathological indexes, and analyzing the obtained multi-level fusion features by using a multi-instance learning network of hierarchical attention to obtain a multi-modal light microscope kidney pathological image analysis result, thereby completing analysis of the light microscope kidney pathological image. The problem that an existing artificial intelligence method is difficult to accurately quantify the light microscope kidney pathological image is solved.

The invention provides a basement membrane sampling method based on glomerular capillary branch characteristics, and relates to the technical field of image recognition, and the method comprises the steps: employing the center and radius of a glomerular region, carrying out the analysis of the mesangial crossing condition of a basement membrane, obtaining a mesangial crossing result, carrying out the region division and sampling window size calculation, and carrying out the calculation of the size of a sampling window. Obtaining a plurality of sectors and corresponding window areas; random sampling is carried out in the sectors to obtain candidate center points; analyzing the candidate center point based on the window area, if the sampling is not qualified, performing failure retry and annealing strategy to adjust the window, and resampling; otherwise, obtaining a qualified window; and combining all qualified windows to obtain a basement membrane sampling result, and completing the basement membrane sampling based on the glomerular capillary branch characteristics. According to the method, the problem of how to perform balanced, low-deviation, reproducible and efficient sampling and labeling on the glomerular basement membrane under the anatomical priori constraint in the light microscope glomerular pathological image is solved.

The present disclosure provides methods of treating or reducing the symptoms of glomerulonephritis in a subject.

Described herein are fusion proteins which include factor H functional domains and may include VHH domains and integrin binding domains, and the use of such fusion proteins in methods of treatment of focal segmental glomerulosclerosis.

The invention relates to the technical field of nephritis medicine, in particular to an AAGN disease metabolism marker, a kit and application of the AAGN disease metabolism marker. In the blood or urine metabolism marker, the blood metabolism marker is prepared from one or more of 6-methyl nicotinamide, hypo-sulphosarcosine, guanosine, allopurinol, 8-hydroxy-2 '-deoxyguanosine, triglyceride or lysophosphatidylcholine; the urine metabolism markers comprise one or more of D-malic acid, leucyl-alanyl-valine, N-hydroxymethyl nicotinamide, DL-tribulus terrestris alkali, isoxotrexate, 1, 3-dimethyluric acid, leucyl-leucyl-phenylalanine, alloandrosterone, enterodiphenol and p-coumarin, and the urine metabolism markers comprise one or more of D-malic acid, leucyl-alanyl-valine, N-hydroxymethyl nicotinamide, DL-tribulus terrestris alkali, isoxotrexate, 1, 3-dimethyluric acid, leucyl- The metabolic marker combination and the kit are used for evaluating the disease activity state of a patient suffering from ANCA-related glomerulonephritis (AAGN), and have good repeatability, stability and biological correlation.

A system and method for diagnosing a patient's renal function, the method comprising delivering a first tracer agent, transmucosally applying a first excitation light to the first tracer agent at the first monitoring site, transmucosally receiving a first fluorescent light emitted from the first tracer agent at the first monitoring site, transforming the received first fluorescent light to produce a first fluorescence signal, processing the first fluorescence signal to determine a first decay rate, and processing the first decay rate of the first fluorescent light to determine a glomerular filtration rate of the patient.

The application discloses a biomarker for diagnosing diabetic nephropathy and application thereof, and relates to the technical field of biological medicine. The biomarker for diagnosing diabetic nephropathy comprises urine MBP-1 or urine MBP-1 / urine creatinine. The urine MBP-1 or urine MBP-1 / urine creatinine biomarker has high identification efficiency: when the urine MBP-1 or urine MBP-1 / urine creatinine ratio is used for identifying DKD and NDRD, the area under the ROC curve (AUC) reaches 0.899, the sensitivity and the specificity are both higher than 0.85, and the two diseases can be efficiently distinguished. The method is non-invasive and convenient: only urine samples need to be collected, the risk of complications such as bleeding and infection caused by invasive operations such as kidney biopsy is avoided, the patient has high acceptance, repeated detection can be performed to dynamically track the disease condition, and special equipment is not needed, so that the method is convenient for clinical popularization and application. Through kidney tissue immunofluorescence verification, MBP-1 is deposited in a large amount in the glomerulus of DKD and is not deposited in NDRD, and thus the kidney local pathological change can be directly reflected.

The fragment omics features provide various properties of a sample (e.g., urine or plasma) and / or a subject. The relative contribution or enrichment of clinically relevant DNA (e.g., the type of renal and non-renal urine cfDNA) is provided utilizing the fragment omics characteristics of urine free DNA. Such measurements may be used to reflect glomerular permeability and to monitor various diseases, such as kidney abnormalities. The fragmenomics characteristics may include corrected urine DNA concentration, length, terminal motif of the urine DNA molecule, and cfDNA molecules from open chromatin regions (OCRs) of one or more tissues. Furthermore, the nuclease activity or other fragmentation process of the cfDNA is determined based on the relative contributions associated with different cfDNA cleavage profiles, which are also used to determine the contribution, pathological grade and gestational age of the cfDNA from the tissue.

The invention belongs to the field of medicine models, and provides a method for constructing a diagnosis model of glomerular crescent bodies of lupus nephritis patients. Comprising the steps of target collection data acquisition, statistical data analysis, inter-group comparison, biological index importance calculation and screening, candidate variable secondary screening, crescent body diagnosis model construction and crescent body diagnosis column graph construction. According to the method, the XGBoost algorithm is utilized to perform initial screening on the pre-prepared variables, and then the unconditional logistic gradual forward regression analysis is utilized to perform secondary screening, so that reliable screening of the crescent marker variables is realized, and in addition, the screening efficiency of the variables is improved; by converting the crescent body diagnosis model into the crescent body diagnosis column diagram, the crescent body diagnosis process is simplified, and the intuition of the model is improved.

This invention belongs to the field of renal pathology testing technology and discloses a method for detecting type IV collagen expression in renal biopsy tissue, comprising the following steps: dewaxing and hydrating paraffin sections of renal biopsy tissue to obtain processed tissue sections; adding the processed tissue sections to a repair solution, heating to boiling, and then cooling to room temperature to obtain repaired tissue sections; adding protease to the repaired tissue sections for enzymatic digestion to obtain enzymatically digested tissue sections; adding a primary antibody to the enzymatically digested tissue sections for preliminary incubation, followed by adding a fluorescein-labeled secondary antibody against the primary antibody for further incubation. This method for detecting type IV collagen expression in renal biopsy tissue is applicable to cases where renal biopsy tissue lacks glomeruli or has too few glomeruli to detect type IV collagen expression. It has high specificity and can provide a new detection method for Alport syndrome in cases where renal biopsy tissue lacks glomeruli.

The application discloses a pathological grading method and device, a storage medium and a computer program product, relates to the technical field of medical image processing, and relates to the technical field of medical image processing. The pathological grading method comprises the following steps: acquiring a light microscope image of a kidney biopsy, and detecting the light microscope image by using a preset glomerulus recognition model to obtain a section image of each glomerulus; according to the section image, determining a proportion result of each type of glomerulus in the light microscope image; and according to the proportion result and a preset pathological grading rule, determining a pathological grading result. The application automatically identifies and classifies the glomerulus in the biopsy image, and automatically classifies according to the clinical pathological grading standard, thereby reducing the work load of the clinician in the pathological grading, and improving the accuracy and efficiency of the pathological grading.

The invention relates to the fields of therapy and drug delivery. It is based on an unexpected finding that a combination of an oligonucleotide-based medicament with a saponin component comprising a penta-cyclic triterpene saponin of a 12,13-dehydrooleanane aglycone core, not only does not appear to be associated with oligonucleotide medicament-induced nephrotoxic effects after systemic administration in vivo, but also that it allows the oligonucleotide-based medicament to enter and act on its nucleic acid target inside of the kidney cells instead of remaining unproductively trapped in renal subcellular compartments or being eliminated into the urine via the renal glomerular filtration system. In line with this finding, herein disclosed are therapeutic combinations, compositions, and formulations, as well as methods of treatment involving their administration, which comprise an oligonucleotide-based medicament that acts on an intracellular nucleic acid target in the kidney cells and / or in the cells of the spleen, being the other blood filtering organ in addition to the kidney, and a saponin component that enables the effective release of said medicament inside of these cells, thus allowing its use at a much lower and safer dose. The provision of the presented herein therapeutic combinations enables effective modulation of gene expression in the kidney and / or spleen cells and, therefore, it opens not only new treatment options for kidney diseases, in particular those involving inflammation and / or splenomegaly, but also for diseases of other organs which affect or are affected by the pathological processes happening in the kidneys and / or in the spleen, in particular being inflammatory processes.

The present invention relates to the novel use of certain piperidinyl-indole derivatives in the treatment of patients suffering from renal diseases or disorders, and in particular for the treatment of patients suffering from C3G (C3 glomerulopathy) and IgAN (IgA nephropathy).

The invention provides a traditional Chinese medicine preparation for treating type 2 diabetic nephropathy and a preparation method and application thereof, and relates to the technical field of traditional Chinese medicine. The traditional Chinese medicine reagent is characterized by comprising the following raw materials: astragalus membranaceus, prepared rehmannia root, dogwood, salvia miltiorrhiza, safflower, poria cocos, rhizoma alismatis, prepared rhubarb, codonopsis pilosula and winged euonymus twig. The traditional Chinese medicine composition has the effects of tonifying qi, activating blood, tonifying kidney and removing turbidity through cooperation of the medicines. The whole formula focuses on the pathogenesis of deficiency stasis and turbid toxin, and the treatment effect is achieved through multiple target points and multi-layer effects. Animal experiments show that the preparation can significantly relieve glomerular mesangial matrix hyperplasia and renal interstitial fibrosis. Clinical experiments show that traditional Chinese medicine symptom scores and curative effects are reduced, blood sugar is controlled, and laboratory indexes related to renal functions are improved.

The application discloses a foot process identification method and device for electron microscope images of chronic kidney disease and terminal equipment, obtains the electron microscope pathological images of chronic kidney disease with labeled foot process position characteristics, and trains a preset deep network architecture through the electron microscope pathological images of chronic kidney disease to obtain a foot process identification model, so that when the electron microscope images of chronic kidney disease to be detected are obtained, the automatic identification of the foot process area corresponding to the electron microscope images to be detected can be realized through the obtained foot process identification model, and the automatic identification of the foot process area of the electron microscope images of chronic kidney disease is realized. The application accurately and quickly identifies the area corresponding to the foot process through the deep learning mode, improves the foot process identification efficiency of the electron microscope images of chronic kidney disease, is favorable to improving the pathological diagnosis and analysis efficiency of various types of glomerulonephritis for pathologists, and can reduce misdiagnosis and missed diagnosis caused by insufficient experience.

A low-salt fasting-mimicking diet (LS-FMD) is provided for promoting kidney regeneration and treating kidney disease. The LS-FMD comprises cyclic dietary interventions that reduce caloric and sodium intake to induce fasting-like metabolic effects while maintaining essential nutrition. In animal models of puromycin-induced nephrosis, LS-FMD cycles restore normal proteinuria levels and improve nephron structure and function relative to untreated controls. The diet activates kidney-specific gene expression programs and promotes a quiescent, non-proliferative state in mature podocytes, supporting renal recovery. In human subjects with chronic kidney disease, administration of fasting-mimicking diet cycles for five days per month over three months reduces proteinuria and improves endothelial function. The invention demonstrates that kidney-specific fasting-mimicking dietary cycles have therapeutic potential for slowing or reversing progressive renal disorders.

This invention discloses an engineered extracellular vesicle and its application in the preparation of products for treating autoimmune diseases. The engineered extracellular vesicle is either an IDO1-overexpressing engineered extracellular vesicle (MSC-IDO1-EVs) or a CSF1-overexpressing engineered extracellular vesicle (MSC-CSF1-EVs). The engineered extracellular vesicles provided by this invention exhibit significant immunosuppressive effects, reducing the secretion of inflammatory cytokines. In animal models, they effectively reduce proteinuria levels, significantly reduce blood dsDNA / ANA levels, effectively alleviate kidney damage caused by autoimmune diseases such as renal immune complex deposition, diffuse thickening of the glomerular basement membrane, and mesangial structural disorder, and reduce overall inflammation levels in mice. The therapeutic effect is significantly superior to that of unmodified MSC-EVs. The engineered extracellular vesicles provided by this invention significantly improve the therapeutic effect on autoimmune diseases.

The disclosure provides at least one entity chosen from compounds of Formula I, a tautomer thereof, a deuterated derivative of that compound or tautomer, and a pharmaceutically acceptable salt of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and / or non-diabetic kidney disease (NDKD).

The invention discloses a classification system for glomerular immunofluorescence images, which relates to the field of medical image processing. The current high reliance on manual labor and the general lack of senior pathologists have further exacerbated the difficulty of diagnosing renal biopsy samples in primary medical institutions. The application of auxiliary systems will be able to significantly improve the efficiency and accuracy of recognition. The classification accuracy of fluorescence intensity and distribution morphology of the present invention reached 90.48% and 90.87% respectively. From the perspective of inference time, the system only takes 13 milliseconds and 12 milliseconds to process each image in fluorescence intensity classification and distribution morphology classification, which is much faster than the 11.06 seconds and 7.84 seconds required by junior pathologists and the 17.14 seconds and 18.26 seconds required by independent senior pathologists. From the perspective of Kappa scores, the conclusions given by the system are almost perfect with the labels and highly consistent with the conclusions given by independent senior pathologists (Substantial agreement, 0.6494 for fluorescence intensity classification and 0.7184 for distribution morphology).

The invention relates to the technical field of biological medicine, in particular to a composition for reducing the occurrence rate of renal edema and improving the glomerular filtration function and application. The composition comprises the following active ingredients: pseudo-ginseng, American ginseng powder and algal polysaccharides, and the active ingredients are crushed, sieved and uniformly mixed to prepare different dosage forms. The composition has remarkable and excellent effects on reducing the occurrence rate of renal edema and improving the glomerular filtration function, and compared with products in the prior art, the composition has the advantage that the use cost of raw materials is reduced.

The invention discloses a glomerular segmentation method based on a multi-scale self-attention mechanism, and relates to the technical field of medical images. According to the method, macrostructures and microcosmic details are extracted in combination with receptive fields of different scales, lesion heterogeneity is effectively dealt with, and the segmentation precision of complex lesion individuals is improved. The edge perception feature fusion module adopts dual-path dense feature fusion and edge deep supervision, and is gradually introduced in a decoding stage, so that lesion feature loss during up-sampling is reduced, and the edge segmentation accuracy and meticulous performance are improved.

The present invention relates to a method for measuring glomerular filtration rate (GFR) ex vivo in a subject that has been administered a contrast agent and that has been subjected to computed tomography (CT) or magnetic resonance imaging (MRI) including an excretion phase, a plain scan phase, an arterial phase, and a renal parenchyma phase or a portal vein phase, the method includes the step of calculating contrast agent clearance from CT or MRI data using manual, automated or semi-automated segmentation software, thereby obtaining a measured GFR.

The invention relates to application of dendrobium officinale tender shoots and / or extracts thereof, in particular to application of dendrobium officinale tender shoots and / or extracts thereof obtained through differentiation induction of dendrobium officinale stem cells in preparation of drugs for treating and / or preventing glomerular cell fibrosis and / or renal podocyte injury related diseases.